Back to Search Start Over

Living on the edge : Substrate competition explains loss of robustness in mitochondrial fatty-acid oxidation disorders

Authors :
Karen van Eunen
Dirk-Jan Reijngoud
K. E. Niezen-Koning
Albert K. Groen
Willemijn J. van Rijt
Anne Claire M F Martines
Rebecca M. Heiner
Barbara M. Bakker
Terry G J Derks
Hjalmar P. Permentier
Justina C. Wolters
Aycha Bleeker
Albert Gerding
Catharina M L Volker-Touw
Analytical Biochemistry
Medicinal Chemistry and Bioanalysis (MCB)
Center for Liver, Digestive and Metabolic Diseases (CLDM)
Lifestyle Medicine (LM)
Source :
BMC Biology, BMC Biology, 14(1):107. BioMed Central Ltd., BMC Biology, 14. BioMed Central Ltd.
Publication Year :
2016

Abstract

Background Defects in genes involved in mitochondrial fatty-acid oxidation (mFAO) reduce the ability of patients to cope with metabolic challenges. mFAO enzymes accept multiple substrates of different chain length, leading to molecular competition among the substrates. Here, we combined computational modeling with quantitative mouse and patient data to investigate whether substrate competition affects pathway robustness in mFAO disorders. Results First, we used comprehensive biochemical analyses of wild-type mice and mice deficient for medium-chain acyl-CoA dehydrogenase (MCAD) to parameterize a detailed computational model of mFAO. Model simulations predicted that MCAD deficiency would have no effect on the pathway flux at low concentrations of the mFAO substrate palmitoyl-CoA. However, high concentrations of palmitoyl-CoA would induce a decline in flux and an accumulation of intermediate metabolites. We proved computationally that the predicted overload behavior was due to substrate competition in the pathway. Second, to study the clinical relevance of this mechanism, we used patients’ metabolite profiles and generated a humanized version of the computational model. While molecular competition did not affect the plasma metabolite profiles during MCAD deficiency, it was a key factor in explaining the characteristic acylcarnitine profiles of multiple acyl-CoA dehydrogenase deficient patients. The patient-specific computational models allowed us to predict the severity of the disease phenotype, providing a proof of principle for the systems medicine approach. Conclusion We conclude that substrate competition is at the basis of the physiology seen in patients with mFAO disorders, a finding that may explain why these patients run a risk of a life-threatening metabolic catastrophe. Electronic supplementary material The online version of this article (doi:10.1186/s12915-016-0327-5) contains supplementary material, which is available to authorized users.

Details

Language :
English
ISSN :
17417007
Database :
OpenAIRE
Journal :
BMC Biology, BMC Biology, 14(1):107. BioMed Central Ltd., BMC Biology, 14. BioMed Central Ltd.
Accession number :
edsair.doi.dedup.....4b21d66b35c86202977865caec5fa6a4